Function and application of interferon regulatory factor 2 combined with protein 2 in treating fatty liver and II type diabetes

• Main Authors: WEI XIANG, LI HONGLIANG, FANG JING
• Format: Patent
• Language: Chinese; English
• Published: 15.02.2017
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The invention takes Alb-cre mouse and IRF2BP2 liver cell specific gene knockout mouse (IRF2BP2 Delta/ Delta) as experimental subjects; by comparing a fat mouse model induced by high fat diet with Alb-cre mouse, the IRF2BP2 Delta/ Delta mouse is fat, and the fasting blood-glucose level is obviously higher than the Alb-cre mouse; the intraperitoneal injection glucose tolerance experiment finds that the gluconic endurance capacity of IRF2BP2 gene knockout mouse is obviously weakened. The liver weight, ratio of liver and weight, pathological staining result and others indicate that the fatty liver lesion of the IRF2BP2 Delta/ Delta mouse after being induced by high fat diet is more serious, and the fat accumulation is significantly increased. As the drug target for screening and treating fatty liver and/or II type diabetes, the accelerant of the IRF2BP2 can be used for preparing the drug for treating fatty liver and/or II type diabetes. 本发明以Alb-cre小鼠与IRF2BP2肝细胞特异性基因敲除小鼠（IRF2BP2）为实验对象，通过高脂饮食诱导的肥胖小鼠模型，发现与Alb-cre小鼠相